https://crstodayeurope.com/news/nevakar-enters-into-licensing-agreement-in-china-for-nvk-002-for-the-treatment-of-myopia-in-children/2478434/daily0.7https://crstodayeurope.com/news/katena-products-acquires-micro-select-instruments/2478435/daily0.7https://crstodayeurope.com/news/members-of-congress-urge-leaders-to-act-to-protect-patient-access-to-surgical-care-and-stop-medicare-cuts/2478433/daily0.7https://crstodayeurope.com/news/strap-technologies-announces-device-to-aid-the-visually-impaired/2478430/daily0.7https://crstodayeurope.com/news/coherent-ships-5000th-oem-excistar-device/2478427/daily0.7https://crstodayeurope.com/news/pfizer-ceo-says-late-november-is-earliest-possible-filing-date-for-covid-19-vaccine-in-us/2478428/daily0.7https://crstodayeurope.com/news/cvs-walgreens-make-deal-with-trump-admin-to-quickly-distribute-covid-19-vaccines-to-nursing-homes/2478429/daily0.7https://crstodayeurope.com/news/biotech-healthcare-launches-bio-hyalur-lvd-for-tranquil-surgeries-calm-clear-eyes/2478424/daily0.7https://crstodayeurope.com/news/appeals-court-skeptical-of-aha-in-lawsuit-over-hhs-price-transparency-rule/2478425/daily0.7https://crstodayeurope.com/news/premium-technology-in-the-covid-19-era/2478477/daily0.7https://crstodayeurope.com/news/concerns-over-surgical-waste-are-clouding-future-of-single-use-device-market/2478423/daily0.7https://crstodayeurope.com/news/blue-light-glasses-improve-sleep-and-work-productivity-iu-research-shows/2478421/daily0.7https://crstodayeurope.com/news/bausch-health-and-bhvi-announce-exclusive-global-licensing-agreement-for-myopia-control-contact-lens/2478422/daily0.7https://crstodayeurope.com/news/bvi-acquires-benz-research-development-strengthening-iol-design-production-and-sales-capabilities/2478419/daily0.7https://crstodayeurope.com/news/new-orbis-international-training-tool-prepares-ophthalmic-nurses-for-the-operating-room/2478417/daily0.7https://crstodayeurope.com/news/study-of-lillys-covid-19-antibody-ly-cov555-paused-over-potential-safety-issue/2478416/daily0.7https://crstodayeurope.com/news/new-world-medical-registers-new-kdb-glide-for-smooth-precise-goniotomy/2478414/daily0.7https://crstodayeurope.com/news/tepezza-data-from-phase-2-clinical-trial-evaluate-longer-term-responses-in-people-living-with-thyroid-eye-disease-ted/2478415/daily0.7https://crstodayeurope.com/news/a-25-year-old-man-becomes-first-in-the-u-s-to-contract-coronavirus-twice/2478412/daily0.7https://crstodayeurope.com/news/will-kids-get-a-covid-19-vaccine-pfizer-to-expand-trial-to-ages-12-and-up/2478411/daily0.7https://crstodayeurope.com/news/hoya-surgical-optics-announces-global-launch-of-clearlog-app/2478409/daily0.7https://crstodayeurope.com/news/jj-pauses-covid-19-vaccine-studies-after-unexplained-illness/2478407/daily0.7https://crstodayeurope.com/news/nicox-announces-plans-for-ncx-4251-phase-2-trial-in-blepharitis/2478408/daily0.7https://crstodayeurope.com/news/santen-joins-forces-with-ophthalmologists-in-the-fight-against-antibiotic-resistance/2478406/daily0.7https://crstodayeurope.com/news/astrazeneca-to-test-long-acting-antibody-treatment-azd7442-in-covid-19-trials/2478403/daily0.7https://crstodayeurope.com/news/bausch-health-licenses-eyenovias-investigational-treatment-for-the-reduction-of-pediatric-myopia-progression-in-children-ages-3-12/2478405/daily0.7https://crstodayeurope.com/news/lilly-incytes-olumiant-shows-significant-effect-on-covid-19-recovery-times/2478401/daily0.7https://crstodayeurope.com/news/cms-alerts-providers-to-changes-to-medicare-advance-loan-repayments-giving-hospitals-more-time/2478399/daily0.7https://crstodayeurope.com/news/azar-lays-out-optimistic-covid-19-vaccine-timeline-of-100-million-doses-by-end-of-2020/2478396/daily0.7https://crstodayeurope.com/news/helpmesee-launches-revolutionary-technology-in-response-to-the-global-cataract-crisis/2478393/daily0.7https://crstodayeurope.com/news/regeneron-asks-fda-to-approve-emergency-use-of-regn-cov2-for-covid-19/2478394/daily0.7https://crstodayeurope.com/news/orbis-international-releases-first-guide-for-creating-simulation-training-programs-for-eye-care-professionals/2478395/daily0.7https://crstodayeurope.com/news/santen-and-orbis-international-announce-long-term-partnership-to-tackle-the-increasing-burden-of-eye-diseases/2478388/daily0.7https://crstodayeurope.com/news/oertli-releases-two-trocar-based-chandelier-solutions/2478389/daily0.7https://crstodayeurope.com/news/eyenovia-to-present-clinical-study-updates-at-the-american-academy-of-optometry-annual-meeting/2478390/daily0.7https://crstodayeurope.com/news/in-recognition-of-world-sight-day-lighthouse-guild-receives-donation-from-bausch-foundation-to-support-computer-training-for-people-with-vision-loss/2478391/daily0.7https://crstodayeurope.com/news/alcon-celebrates-world-sight-day-2020-and-continues-commitment-to-improving-worldwide-access-to-eye-care/2478392/daily0.7https://crstodayeurope.com/news/equinox-ophthalmic-appoints-stuart-raetzman-as-executive-chair/2478384/daily0.7https://crstodayeurope.com/news/gsk-vir-biotechnology-move-anti-sars-cov-2-monoclonal-antibody-into-phase-3/2478385/daily0.7https://crstodayeurope.com/news/fda-releases-eua-guidelines-that-may-extend-review-time-for-covid-19-vaccines/2478381/daily0.7https://crstodayeurope.com/news/zeiss-partners-with-microsoft-for-better-patient-care-through-data-driven-health-care/2478383/daily0.7https://crstodayeurope.com/news/john-weiss-launches-the-merilas-810-shortpulse-laser-in-the-uk/2478380/daily0.7https://crstodayeurope.com/news/dell-hp-lenovo-and-acer-to-announce-new-eyesafe-products-at-the-blue-light-summit-2020/2478378/daily0.7https://crstodayeurope.com/news/tarsus-releases-data-from-io-and-europa-trials-for-tp-03-to-treat-demodex-blepharitis-and-begins-phase-2b-3-saturn-1-trial/2478374/daily0.7https://crstodayeurope.com/news/new-dates-for-vision-expo-east-2021/2478371/daily0.7https://crstodayeurope.com/news/uh-professor-developing-new-technology-to-detect-lens-elasticity-associated-with-presbyopia/2478372/daily0.7https://crstodayeurope.com/news/new-survey-finds-most-people-say-they-know-the-importance-of-an-annual-eye-exam-but-theyre-not-getting-one/2478373/daily0.7https://crstodayeurope.com/news/sun-ophthalmics-to-present-e-posters-at-aaopt/2478370/daily0.7https://crstodayeurope.com/news/ooss-submits-comments-to-cms-on-2021-proposed-asc-payment-regulation/2478368/daily0.7https://crstodayeurope.com/news/tearsolutions-announces-results-from-primary-sjocc88grens-syndrome-trial-and-appoints-anil-asrani-president-and-ceo/2478369/daily0.7https://crstodayeurope.com/news/tarsius-pharma-achieves-positive-results-in-proof-of-concept-study-for-trs01-targeting-uveitis/2478367/daily0.7https://crstodayeurope.com/news/celebrities-athletes-and-authors-read-bedtime-stories-on-world-sight-day/2478366/daily0.7https://crstodayeurope.com/news/renowned-ophthalmologist-and-humanitarian-alan-s-crandall-md-dies-at-age-73/2478360/daily0.7https://crstodayeurope.com/news/ema-starts-rolling-review-of-astrazenecas-covid-19-vaccine-candidate-azd1222/2478359/daily0.7https://crstodayeurope.com/news/pooled-analysis-of-data-from-two-phase-3-clinical-trials-of-upneeq-for-acquired-ptosis-published/2478357/daily0.7https://crstodayeurope.com/news/orasis-raises-30-million-to-advance-the-clinical-development-of-novel-treatment-for-presbyopia/2478356/daily0.7https://crstodayeurope.com/news/telemedicine-and-combating-patient-misinformation/2478448/daily0.7https://crstodayeurope.com/news/new-company-tearrestore-launches-reusable-heat-packs-to-target-the-meibomian-glands/2478355/daily0.7https://crstodayeurope.com/news/istar-medical-reports-positive-6-month-data-for-miniject-device/2478354/daily0.7https://crstodayeurope.com/news/centricity-vision-appoints-jim-mazzo-to-its-board-of-directors/2478353/daily0.7https://crstodayeurope.com/news/modernas-mrna-1273-covid-19-vaccine-generates-immune-responses-in-older-adults/2478351/daily0.7https://crstodayeurope.com/news/zeiss-introduces-new-solution-enhancements-for-procedure-workflows-at-escrs-and-euretina/2478352/daily0.7https://crstodayeurope.com/news/biotech-healthcare-launches-optiflex-trio-trifocal-iol/2478350/daily0.7https://crstodayeurope.com/news/bristol-amgen-teva-ceos-among-execs-to-testify-at-house-drug-pricing-hearings-next-week/2478346/daily0.7https://crstodayeurope.com/news/early-data-show-regenerons-antibody-cocktail-cuts-viral-load-eases-covid-19-symptoms/2478347/daily0.7https://crstodayeurope.com/news/employers-will-need-to-respond-carefully-amid-roller-coaster-of-health-costs-during-covid-19/2478345/daily0.7https://crstodayeurope.com/news/inovios-covid-19-vaccine-candidate-ino-4800-hit-by-fda-partial-hold/2478341/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-announces-first-patients-dosed-in-phase-2-clinical-trial-of-otx-csi-for-the-treatment-of-dry-eye-disease/2478343/daily0.7https://crstodayeurope.com/news/alcon-focuses-on-presbyopia-correcting-iol-innovation-and-the-new-normal-at-the-virtual-escrs-2020/2478344/daily0.7https://crstodayeurope.com/news/aerie-pharmaceuticals-announces-acceptance-of-its-investigational-new-drug-application-for-ar-15512-eye-drop-for-dry-eye-disease/2478340/daily0.7https://crstodayeurope.com/news/study-essilors-stellest-lens-slows-down-myopia-progression-in-children-by-more-than-60-after-one-year/2478339/daily0.7https://crstodayeurope.com/news/haag-streit-uk-announces-launch-of-the-mr-q-and-mr-q-supine-laser-systems-in-the-uk/2478337/daily0.7https://crstodayeurope.com/news/ziemer-announces-ce-mark-clearance-for-its-new-ablation-laser-aquariuz/2478334/daily0.7https://crstodayeurope.com/news/johnson-johnson-vision-launches-new-eye-care-solutions-and-showcases-latest-clinical-data-at-escrs-2020-virtual-annual-meeting/2478335/daily0.7https://crstodayeurope.com/news/aurinia-completes-final-patient-treatment-in-audrey-phase-2-3-clinical-trial-of-voclosporin-ophthalmic-solution-for-dry-eye/2478336/daily0.7https://crstodayeurope.com/news/johnson-johnson-vision-to-introduce-tecnis-synergy-toric-ii-iol-and-catalys-system-cos-6-0-software-at-the-escrs-2020/2478331/daily0.7https://crstodayeurope.com/news/jjs-covid-19-vaccine-highly-immunogenic-in-early-stage-testing/2478332/daily0.7https://crstodayeurope.com/news/visus-therapeutics-launches-and-announces-clinical-development-program-for-novel-presbyopia-eye-drop/2478333/daily0.7https://crstodayeurope.com/news/novavax-begins-phase-3-coronavirus-vaccine-trial-in-uk/2478330/daily0.7https://crstodayeurope.com/news/fda-grants-orphan-drug-designation-for-neurophth-therapeutics-gene-therapy-for-lhon/2478326/daily0.7https://crstodayeurope.com/news/new-products-launched-by-micro-labs-usa-inc/2478327/daily0.7https://crstodayeurope.com/news/trump-signs-executive-orders-on-preexisting-condition-protections-surprise-billing/2478328/daily0.7https://crstodayeurope.com/news/fda-approves-bausch-lomb-alaway-preservative-free-ophthalmic-solution/2478329/daily0.7https://crstodayeurope.com/news/house-government-funding-bill-gives-providers-relief-on-medicare-advance-payments/2478324/daily0.7https://crstodayeurope.com/news/optimo-medical-gets-support-by-innosuisse-to-enter-the-us-market/2478322/daily0.7https://crstodayeurope.com/news/bausch-health-announces-vyzulta-now-approved-in-seven-countries-expanded-coverage-in-canada/2478323/daily0.7https://crstodayeurope.com/news/uk-to-run-challenge-trials-for-covid-19-vaccines-report/2478317/daily0.7https://crstodayeurope.com/news/whitney-hauser-od-faao-joins-novartis-ophthalmics/2478318/daily0.7https://crstodayeurope.com/news/us-eye-network-expands-into-southeastern-us-through-partnership-with-carolina-eyecare-physicians/2478319/daily0.7https://crstodayeurope.com/news/fight-for-sight-and-prevent-blindness-announce-recipient-of-the-2020-joanne-angle-public-health-award/2478320/daily0.7https://crstodayeurope.com/news/aerie-pharmaceuticals-announces-interim-90-day-topline-data-from-its-6-month-mercury-3-clinical-trial-in-europe/2478321/daily0.7https://crstodayeurope.com/news/nicox-selects-0-1-ncx-470-dose-in-adaptive-stage-of-mont-blanc-phase-3-glaucoma-trial/2478316/daily0.7https://crstodayeurope.com/news/kkr-to-acquire-1-800-contacts-from-aea-investors/2478313/daily0.7https://crstodayeurope.com/news/fauci-offers-defense-of-why-americans-can-trust-the-approval-process-for-a-potential-covid-19-vaccine/2478314/daily0.7https://crstodayeurope.com/news/johnson-johnson-starts-phase-3-study-of-covid-19-vaccine-candidate/2478315/daily0.7https://crstodayeurope.com/news/alsanza-announces-launch-of-alsafit-fourier-optic-iol/2478312/daily0.7https://crstodayeurope.com/news/emmecell-announces-fda-acceptance-of-ind-application-for-eo2002-in-corneal-edema/2478310/daily0.7https://crstodayeurope.com/news/lumenis-unveils-its-first-us-tour-with-launch-of-mobile-outdoor-tradeshow-booth/2478311/daily0.7https://crstodayeurope.com/news/analysis-ambulatory-surgery-centers-reduce-medicare-costs-by-more-than-4-billion-each-year/2478306/daily0.7https://crstodayeurope.com/news/coopervision-recaps-complimentary-contact-lens-program-for-essential-hospital-workers/2478307/daily0.7https://crstodayeurope.com/news/moodys-hospital-financial-outlook-worse-as-covid-19-relief-funds-start-to-dwindle/2478308/daily0.7https://crstodayeurope.com/news/rayner-to-launch-rayone-emv-enhanced-monofocal-iol/2478303/daily0.7https://crstodayeurope.com/news/biomarker-indicating-neurodegeneration-identified-in-the-eye/2478302/daily0.7https://crstodayeurope.com/news/liminal-biosciences-provides-update-on-progress-on-bla-for-ryplazim-plasminogen/2478301/daily0.7https://crstodayeurope.com/news/roches-actemra-roactemra-cuts-need-for-ventilator-use-in-covid-19-pneumonia/2478299/daily0.7https://crstodayeurope.com/news/bausch-health-to-acquire-option-to-purchase-all-ophthalmology-assets-of-allegro-ophthalmics/2478300/daily0.7https://crstodayeurope.com/news/study-finds-novel-mechanism-that-may-confer-protection-against-glaucoma/2478298/daily0.7https://crstodayeurope.com/news/neuro-optometric-rehabilitation-association-announces-appointments-of-new-executive-and-advisory-board-officers/2478297/daily0.7https://crstodayeurope.com/news/nicox-announces-senior-management-change/2478295/daily0.7https://crstodayeurope.com/news/biontech-snaps-up-novartis-german-site-to-expand-coronavirus-vaccine-output/2478296/daily0.7https://crstodayeurope.com/news/ceo-says-moderna-will-know-by-november-if-covid-19-vaccine-works/2478294/daily0.7https://crstodayeurope.com/news/ophthalmic-societies-call-on-fda-to-keep-moxifloxacin-on-bulk-substance-list/2478293/daily0.7https://crstodayeurope.com/news/metlife-to-acquire-versant-health-owner-of-davis-vision-and-superior-vision/2478292/daily0.7https://crstodayeurope.com/news/oxford-says-astrazeneca-trial-illnesses-may-not-be-linked-to-covid-19-vaccine/2478290/daily0.7https://crstodayeurope.com/news/us-plans-to-ship-first-coronavirus-vaccines-within-24-hours-of-fda-approval/2478291/daily0.7https://crstodayeurope.com/news/santen-acquires-eyevance-pharmaceutical/2478289/daily0.7https://crstodayeurope.com/news/facebook-and-essilorluxottica-announce-collaboration-for-smart-glasses/2478288/daily0.7https://crstodayeurope.com/news/gensight-biologics-submits-eu-marketing-authorization-application-for-lhon-gene-therapy-lumevoq/2478287/daily0.7https://crstodayeurope.com/news/medscape-us-and-international-physicians-covid-19-experience-report-risk-burnout-loneliness/2478285/daily0.7https://crstodayeurope.com/news/fda-probes-whether-to-allow-astrazeneca-to-resume-covid-19-vaccine-trial-in-us/2478286/daily0.7https://crstodayeurope.com/news/aviceda-therapeutics-appoints-biopharma-and-business-veterans-to-its-board-of-directors/2478284/daily0.7https://crstodayeurope.com/news/recordati-rare-diseases-announces-availability-of-cystadrops-in-the-us/2478283/daily0.7https://crstodayeurope.com/news/aerie-pharmaceuticals-announces-fda-approval-of-its-athlone-ireland-facility-for-production-of-rhopressa/2478282/daily0.7https://crstodayeurope.com/news/bvi-introduces-patient-packs-aimed-at-helping-us-ophthalmologists-bring-patients-back/2478280/daily0.7https://crstodayeurope.com/news/lilly-incytes-olumiant-cuts-recovery-time-when-added-to-veklury-in-hospitalized-covid-19-patients/2478281/daily0.7https://crstodayeurope.com/news/keeler-partners-with-medical-device-maker-olleyes/2478278/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-3-clinical-trial-of-dextenza-for-the-treatment-of-post-surgical-ocular-inflammation-and-pain-in-children/2478274/daily0.7https://crstodayeurope.com/news/staar-surgical-announces-completion-of-patient-enrollment-in-evo-implantable-lens-us-clinical-trial/2478275/daily0.7https://crstodayeurope.com/news/5-reasons-why-medical-meetings-will-never-be-the-same/2478276/daily0.7https://crstodayeurope.com/news/astrazeneca-resumes-covid-19-vaccine-trials/2478273/daily0.7https://crstodayeurope.com/news/telemedicine-in-the-covid-19-era/2478413/daily0.7https://crstodayeurope.com/news/kala-pharmaceuticals-to-host-key-opinion-leader-symposium-on-unmet-need-in-dry-eye-disease-and-potential-for-eysuvis/2478270/daily0.7https://crstodayeurope.com/news/astrazeneca-must-explain-spinal-ailment-to-resume-vaccine-trial/2478268/daily0.7https://crstodayeurope.com/news/helpmesee-names-saro-jahani-as-president-and-ceo/2478266/daily0.7https://crstodayeurope.com/news/study-to-investigate-if-those-with-diabetic-eye-disease-are-at-greater-risk-of-covid-19-complications/2478267/daily0.7https://crstodayeurope.com/news/sight-sciences-presents-additional-results-of-olympia-study-of-signs-and-symptoms-of-dry-eye-disease-using-tearcare/2478263/daily0.7https://crstodayeurope.com/news/the-vision-council-launches-new-brand-identity-and-member-focused-website/2478260/daily0.7https://crstodayeurope.com/news/zeiss-launches-vision-in-county-cataract-development-program-in-shandong-china/2478256/daily0.7https://crstodayeurope.com/news/astrazeneca-pauses-covid-19-vaccine-trial-amid-safety-concern/2478258/daily0.7https://crstodayeurope.com/news/ama-issues-cpt-category-iii-codes-for-artificial-iris-implantation/2478255/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-announces-resolution-of-fda-warning-letter-related-to-resure-sealant/2478250/daily0.7https://crstodayeurope.com/news/orbis-international-announces-new-ceo-president/2478251/daily0.7https://crstodayeurope.com/news/independent-smaller-hospitals-will-need-to-make-tough-choices-to-survive-covid-19-financial-crisis-analysis/2478252/daily0.7https://crstodayeurope.com/news/bvi-expands-malosa-single-use-instrument-range-in-the-us/2478253/daily0.7https://crstodayeurope.com/news/liminal-biosciences-announces-resubmission-of-biologics-license-application-to-fda-for-ryplazim/2478254/daily0.7https://crstodayeurope.com/news/covid-19-vaccine-developers-seek-to-reassure-public-over-safety/2478249/daily0.7https://crstodayeurope.com/news/saliva-covid-19-test-as-good-as-perhaps-beats-nasal-swab-study/2478248/daily0.7https://crstodayeurope.com/news/graybug-vision-appoints-robert-breuil-as-chief-financial-officer/2478245/daily0.7https://crstodayeurope.com/news/ceo-expects-pfizer-will-know-by-october-if-covid-19-vaccine-works/2478246/daily0.7https://crstodayeurope.com/news/quantel-medical-lauches-mosar-high-definition-imaging-system-for-for-easyret/2478247/daily0.7https://crstodayeurope.com/news/nearly-one-quarter-of-chinese-children-hospitalized-with-covid-19-developed-eye-symptoms/2478244/daily0.7https://crstodayeurope.com/news/sanofi-gsk-start-phase-1-2-study-of-covid-19-vaccine-candidate/2478239/daily0.7https://crstodayeurope.com/news/analysis-finds-corticosteroids-cut-risk-of-death-in-critically-ill-covid-19-patients/2478240/daily0.7https://crstodayeurope.com/news/nih-panel-finds-insufficient-data-to-support-use-of-plasma-for-covid-19/2478235/daily0.7https://crstodayeurope.com/news/hhs-bids-250-million-contract-meant-to-defeat-despair-and-inspire-hope-on-coronavirus/2478236/daily0.7https://crstodayeurope.com/news/nicox-completes-enrollment-of-the-adaptive-design-cohort-of-ncx-470-mont-blanc-phase-3-glaucoma-trial/2478234/daily0.7https://crstodayeurope.com/news/injectsense-receives-breakthrough-device-program-designation-from-fda-for-iop-monitoring-system/2478233/daily0.7https://crstodayeurope.com/news/astrazeneca-kicks-off-phase-3-study-of-covid-19-vaccine-azd1222-in-the-us/2478229/daily0.7https://crstodayeurope.com/news/pandemic-will-leave-children-with-less-access-to-eye-care-new-survey-shows/2478227/daily0.7https://crstodayeurope.com/news/americans-see-hospitals-as-more-trustworthy-than-fda-or-cdc-on-covid-19-vaccine-information-poll-finds/2478225/daily0.7https://crstodayeurope.com/news/core-alerts-practitioners-to-mask-associated-dry-eye-made/2478221/daily0.7https://crstodayeurope.com/news/regenerx-joint-venture-expects-to-complete-phase-3-dry-eye-trial-in-november-2020/2478222/daily0.7https://crstodayeurope.com/news/hospitals-could-be-facing-lower-patient-volumes-for-a-while-due-to-covid-19-how-are-they-responding/2478223/daily0.7https://crstodayeurope.com/news/fda-expands-emergency-use-for-gileads-veklury-to-all-hospitalized-covid-19-patients/2478218/daily0.7https://crstodayeurope.com/news/health-canada-authorizes-enspryng-for-canadians-living-with-neuromyelitis-optica-spectrum-disorder/2478219/daily0.7https://crstodayeurope.com/news/topcon-announces-the-us-launch-of-aladdin-m/2478217/daily0.7https://crstodayeurope.com/news/studies-evaluate-effectiveness-of-intracameral-omidria-for-reducing-postoperative-cme/2478216/daily0.7https://crstodayeurope.com/news/vision-expo-to-host-virtual-career-zone-event-on-september-22/2478215/daily0.7https://crstodayeurope.com/news/amazon-enters-health-tracking-space-with-halo-wristband-app-debut/2478213/daily0.7https://crstodayeurope.com/news/12m-have-likely-lost-employer-coverage-amid-covid-19-report/2478214/daily0.7https://crstodayeurope.com/news/patient-comanagement-and-referrals-in-the-age-of-covid-19/2479508/daily0.7https://crstodayeurope.com/news/modernas-covid-19-vaccine-candidate-shows-promise-in-older-adults/2478211/daily0.7https://crstodayeurope.com/news/prevent-blindness-to-kick-off-virtual-persons-of-vision-award-event-honoring-vsp-global/2478212/daily0.7https://crstodayeurope.com/news/zeiss-adds-central-topography-feature-to-iol-master-700/2478210/daily0.7https://crstodayeurope.com/news/educating-the-next-generation-of-surgeons-during-covid-19/2479509/daily0.7https://crstodayeurope.com/news/seva-foundation-partners-with-irisvision-to-democratize-vision-care-through-innovation/2478208/daily0.7https://crstodayeurope.com/news/pdl-biopharma-announces-filing-of-a-form-10-registration-statement-with-the-sec-for-a-potential-spin-off-of-lensar-to-pdls-stockholders/2478207/daily0.7https://crstodayeurope.com/news/clearside-biomedical-expands-patent-portfolio-in-the-us-and-europe/2478203/daily0.7https://crstodayeurope.com/news/dosing-begins-in-phase-1-study-of-astrazenecas-antibody-combination-for-covid-19/2478204/daily0.7https://crstodayeurope.com/news/sight-sciences-announces-positive-interim-results-from-trial-of-the-omni-surgical-system-in-open-angle-glaucoma/2478205/daily0.7https://crstodayeurope.com/news/fda-approves-cystadrops-for-the-ocular-manifestations-of-cystinosis/2478201/daily0.7https://crstodayeurope.com/news/gyroscope-therapeutics-announces-fda-clearance-for-orbit-subretinal-delivery-system/2478198/daily0.7https://crstodayeurope.com/news/hospital-operating-margins-down-28-through-july-report/2478199/daily0.7https://crstodayeurope.com/news/prevent-blindness-data-shows-basketball-as-cause-of-most-sports-related-eye-injuries/2478197/daily0.7https://crstodayeurope.com/news/eu-wraps-up-advanced-talks-with-moderna-for-covid-19-vaccine-supply-deal/2478195/daily0.7https://crstodayeurope.com/news/sifi-reports-positive-results-from-044-si-phase-3-clinical-trial-of-netildex-gel/2478196/daily0.7https://crstodayeurope.com/news/neuroptika-completes-enrollment-in-phase-2-clinical-trial-for-dry-eye-disease/2478192/daily0.7https://crstodayeurope.com/news/nanodropper-awarded-a-phase-2-sbir-contract-with-us-air-force/2478191/daily0.7https://crstodayeurope.com/news/fda-grants-eua-for-convalescent-plasma-in-hospitalized-covid-19-patients/2478190/daily0.7https://crstodayeurope.com/news/fewer-side-effects-helped-spur-pfizer-biontech-to-advance-bnt162b2-over-earlier-covid-19-vaccine-candidate/2478189/daily0.7https://crstodayeurope.com/news/cdc-director-warns-of-major-public-health-complications-if-public-doesnt-take-flu-and-covid-19-seriously/2478188/daily0.7https://crstodayeurope.com/news/kubota-vision-receives-orphan-products-clinical-trials-grants-to-emixustat-for-stargardt-disease/2478187/daily0.7https://crstodayeurope.com/news/jj-looking-to-enroll-60000-participants-in-coronavirus-vaccine-trial/2478185/daily0.7https://crstodayeurope.com/news/medicare-spent-1-4b-on-discarded-part-b-drugs-in-2017-and-2018-report/2478186/daily0.7https://crstodayeurope.com/news/wsj-troubled-covid-19-data-system-returning-to-cdc/2478184/daily0.7https://crstodayeurope.com/news/lensgen-closes-10-million-financing-and-welcomes-james-v-mazzo-to-its-board-of-directors/2478182/daily0.7https://crstodayeurope.com/news/safer-and-more-effective-glaucoma-surgical-options-will-drive-surgery-device-treatment-penetration-over-next-five-years/2478181/daily0.7https://crstodayeurope.com/news/supreme-court-to-hear-arguments-on-pivotal-case-that-decides-fate-of-aca-after-election/2478180/daily0.7https://crstodayeurope.com/news/what-happens-during-a-covid-19-resurgence/2479510/daily0.7https://crstodayeurope.com/news/trefoil-therapeutics-begins-first-clinical-trial-of-regenerative-treatment-for-patients-with-corneal-endothelial-dystrophies/2478175/daily0.7https://crstodayeurope.com/news/regeneron-boosts-production-capacity-for-covid-19-antibody-cocktail-via-deal-with-roche/2478176/daily0.7https://crstodayeurope.com/news/johnson-johnson-to-buy-momenta-for-6-5-billion/2478177/daily0.7https://crstodayeurope.com/news/nearly-half-of-physicians-believe-it-will-take-a-year-to-get-covid-19-under-control/2478174/daily0.7https://crstodayeurope.com/news/bvi-launches-ipure-aspheric-monofocal-iol-in-the-us/2478172/daily0.7https://crstodayeurope.com/news/why-johnson-johnson-is-investing-in-this-niche-telehealth-startup/2478171/daily0.7https://crstodayeurope.com/news/haag-streit-usa-introduces-new-core-surgical-chair-for-surgeons/2478169/daily0.7https://crstodayeurope.com/news/sanofi-enters-3-7-billion-deal-to-buy-principia-biopharma/2478166/daily0.7https://crstodayeurope.com/news/how-covid-19-is-shaking-up-medical-education-for-good/2478168/daily0.7https://crstodayeurope.com/news/fda-approves-genentechs-enspryng-for-neuromyelitis-optica-spectrum-disorder/2478165/daily0.7https://crstodayeurope.com/news/avellino-hits-1-million-genetic-test-milestone/2478164/daily0.7https://crstodayeurope.com/news/comparison-of-mask-types-finds-key-differences-in-filtration/2478161/daily0.7https://crstodayeurope.com/news/multifocal-contact-lenses-with-high-add-power-help-slow-myopia-progression/2478162/daily0.7https://crstodayeurope.com/news/eu-wraps-up-exploratory-talks-with-jj-to-secure-coronavirus-vaccine/2478163/daily0.7https://crstodayeurope.com/news/johnson-johnson-vision-launches-tecnis-synergy-and-tecnis-eyhance-iols-in-canada/2478160/daily0.7https://crstodayeurope.com/news/tom-frinzi-joins-corneagen-board-as-executive-chair/2478159/daily0.7https://crstodayeurope.com/news/tearclear-raises-22m-in-series-b-funding/2478158/daily0.7https://crstodayeurope.com/news/bvi-partners-with-hvo-to-provide-ppe-for-healthcare-workers/2478155/daily0.7https://crstodayeurope.com/news/academy-2020-moves-online-due-to-covid-19/2478154/daily0.7https://crstodayeurope.com/news/nicox-partners-zerviate-in-the-gulf-and-arab-markets/2478152/daily0.7https://crstodayeurope.com/news/us-secures-at-least-100-million-doses-of-modernas-covid-19-vaccine-for-1-5-billion/2478151/daily0.7https://crstodayeurope.com/news/diagnostic-market-sees-new-demand-due-to-effects-of-covid-19/2478150/daily0.7https://crstodayeurope.com/news/vsy-biotechnology-launches-enova-glistening-free-hydrophobic-acrylic-iol/2478147/daily0.7https://crstodayeurope.com/news/gilead-files-for-us-approval-of-veklury-to-treat-covid-19/2478148/daily0.7https://crstodayeurope.com/news/russias-approval-of-virus-vaccine-greeted-with-some-alarm/2478146/daily0.7https://crstodayeurope.com/news/eyenovia-and-arctic-vision-announce-license-agreement-to-develop-and-commercialize-products-in-greater-china-and-south-korea/2478143/daily0.7https://crstodayeurope.com/news/at-least-97000-children-tested-positive-for-coronavirus-in-last-2-weeks-of-july-at-least-97000-children-tested-positive-for-the-coronavirus-during-the-last-two-weeks-of-july-according-to-a-new-revi/2478145/daily0.7https://crstodayeurope.com/news/omeros-reports-recovery-and-survival-of-all-patients-in-study-evaluating-narsoplimab-for-treatment-of-covid-19/2478141/daily0.7https://crstodayeurope.com/news/sight-sciences-announces-first-patients-enrolled-in-orion-clinical-trial-of-the-omni-surgical-system/2478138/daily0.7https://crstodayeurope.com/news/serum-institute-to-produce-covid-19-vaccines-from-astrazeneca-novavax/2478139/daily0.7https://crstodayeurope.com/news/technology-and-covid-19-necessity-is-the-mother-of-invention/2479511/daily0.7https://crstodayeurope.com/news/medicare-sticks-with-e-m-pay-plan-over-some-groups-objections/2478136/daily0.7https://crstodayeurope.com/news/astrazeneca-takes-covid-19-vaccine-to-china-with-biokangtai-deal-for-200m-dose-capacity-by-2021/2478134/daily0.7https://crstodayeurope.com/news/trump-signs-order-to-boost-production-of-essential-drugs-in-us/2478135/daily0.7https://crstodayeurope.com/news/aao-planned-medicare-cuts-deal-heavy-blow-to-nations-ophthalmologists/2478132/daily0.7https://crstodayeurope.com/news/johnson-johnson-forges-1-billion-pact-to-supply-us-with-covid-19-vaccine/2478133/daily0.7https://crstodayeurope.com/news/bausch-health-to-spin-off-eye-care-business/2478131/daily0.7https://crstodayeurope.com/news/new-evidence-suggests-young-children-spread-covid-19-more-efficiently-than-adults/2478128/daily0.7https://crstodayeurope.com/news/cms-proposes-changes-to-docs-medicare-payments-for-2021-including-payment-cuts-for-some-specialties/2478125/daily0.7https://crstodayeurope.com/news/researchers-discover-predictor-of-laser-treatment-success-in-patients-with-glaucoma/2478127/daily0.7https://crstodayeurope.com/news/palatin-technologies-announces-completion-of-enrollment-of-phase-2-study-with-pl9643-for-the-treatment-of-dry-eye-disease/2478124/daily0.7https://crstodayeurope.com/news/novavax-reports-positive-early-results-for-experimental-covid-19-vaccine-nvx-cov2373/2478122/daily0.7https://crstodayeurope.com/news/iapb-rethinking-global-health-means-including-eye-health/2478120/daily0.7https://crstodayeurope.com/news/winning-strategies-for-a-new-phase-of-practice/2478121/daily0.7https://crstodayeurope.com/news/eli-lilly-starts-late-stage-study-of-neutralizing-antibody-against-sars-cov-2-in-nursing-homes/2478118/daily0.7https://crstodayeurope.com/news/eyepoint-pharmaceuticals-and-imprimisrx-announce-u-s-commercial-alliance-for-dexycu/2478119/daily0.7https://crstodayeurope.com/news/american-college-of-surgeons-strongly-opposes-proposed-medicare-physician-fee-schedule/2478117/daily0.7https://crstodayeurope.com/news/proposed-medicare-physician-fee-schedule-rule-jeopardizes-patient-care-argues-the-surgical-care-coalition/2478115/daily0.7https://crstodayeurope.com/news/can-you-get-covid-19-through-your-eyes-possibly/2478112/daily0.7https://crstodayeurope.com/news/sanofi-gsk-gain-2-1-billion-from-us-government-for-development-supply-of-covid-19-vaccine/2478107/daily0.7https://crstodayeurope.com/news/some-providers-face-daunting-repayment-deadline-for-medicare-advance-loans/2478108/daily0.7https://crstodayeurope.com/news/the-vision-council-releases-2019-vision-watch-cataract-report/2478110/daily0.7https://crstodayeurope.com/news/aao-acas-medicaid-expansion-failed-to-improve-diabetic-dilated-eye-exam-rates-long-term/2478111/daily0.7https://crstodayeurope.com/news/which-hcps-are-most-likely-to-get-covid-vaccine/2478106/daily0.7https://crstodayeurope.com/news/refocus-eye-health-acquires-opticare-eye-health-vision-centers/2478105/daily0.7https://crstodayeurope.com/news/ior-partners-welcomes-tom-frinzi-to-their-board/2478104/daily0.7https://crstodayeurope.com/news/new-topline-tepezza-data-underscore-its-efficacy-in-potential-for-retreatment-in-people-living-with-thyroid-eye-disease-ted/2478101/daily0.7https://crstodayeurope.com/news/face-to-face-meetings-between-pharma-and-doctors-are-on-the-up/2478102/daily0.7https://crstodayeurope.com/news/how-covid-19-causes-smell-loss/2478103/daily0.7https://crstodayeurope.com/news/vitamin-b3-shows-promise-for-glaucoma-patients-in-clinical-trial/2478100/daily0.7https://crstodayeurope.com/news/jj-vaccine-protects-monkeys-from-covid-with-single-shot/2478099/daily0.7https://crstodayeurope.com/news/kubota-vision-demonstrates-3d-imaging-capabilities-using-ai-on-pbos/2478095/daily0.7https://crstodayeurope.com/news/roches-actemra-roactemra-fails-in-severe-covid-19-associated-pneumonia-study/2478097/daily0.7https://crstodayeurope.com/news/microoptx-completes-patient-enrollment-in-initial-phase-of-us-pivotal-trial-for-the-beacon-aqueous-microshunt/2478098/daily0.7https://crstodayeurope.com/news/tearlab-appoints-adam-szaronos-as-chief-commercial-officer/2478094/daily0.7https://crstodayeurope.com/news/as-ophthalmology-clinics-reopen-new-questions-abound/2478093/daily0.7https://crstodayeurope.com/news/senate-gop-outlines-next-coronavirus-relief-bill-as-deadline-for-enhanced-unemployment-benefits-nears/2478090/daily0.7https://crstodayeurope.com/news/bascom-palmer-eye-institute-ranked-nations-no-1-in-ophthalmology-for-19th-time/2478089/daily0.7https://crstodayeurope.com/news/acufocus-announces-extended-diopter-range-for-the-ic-8-small-aperture-iol/2478087/daily0.7https://crstodayeurope.com/news/new-licensing-agreement-accelerates-the-development-of-iacta-pharmaceuticals-novel-dry-eye-disease-and-allergic-conjunctivitis-treatments-in-china-and-southeast-asia/2478088/daily0.7https://crstodayeurope.com/news/pfizer-biontech-pick-bnt162b2-to-advance-into-phase-2-3-coronavirus-vaccine-study/2478084/daily0.7https://crstodayeurope.com/news/dosing-begins-in-modernas-late-stage-study-of-covid-19-vaccine-candidate/2478085/daily0.7https://crstodayeurope.com/news/us-news-releases-2020-21-best-hospitals-rankings-and-special-hospital-heroes-series/2478086/daily0.7https://crstodayeurope.com/news/covid-19-vaccine-candidate-heads-to-widespread-testing-in-u-s/2478083/daily0.7https://crstodayeurope.com/news/hanita-lenses-announces-launch-of-intensity-iol/2478082/daily0.7https://crstodayeurope.com/news/oculis-announces-successful-end-of-phase-2-meeting-with-the-fda-for-ocs-01-in-two-ophthalmology-indications/2478076/daily0.7https://crstodayeurope.com/news/trump-signs-executive-orders-on-drug-pricing-resurrect-rules-on-rebates-importation/2478077/daily0.7https://crstodayeurope.com/news/covid-19-clinical-and-surgical-protocols-which-changes-are-here-to-stay/2479512/daily0.7https://crstodayeurope.com/news/nih-selects-dr-michael-chiang-as-director-of-the-national-eye-institute/2478074/daily0.7https://crstodayeurope.com/news/algorithm-compares-risk-of-cancelled-ophthalmology-appointments-against-covid-19/2478075/daily0.7https://crstodayeurope.com/news/pepcid-as-a-coronavirus-remedy-trumps-21-million-gamble-fizzled/2478070/daily0.7https://crstodayeurope.com/news/moderna-loses-us-patent-challenge-that-could-affect-covid-19-vaccine/2478072/daily0.7https://crstodayeurope.com/news/researchers-capture-cell-level-details-of-curved-cornea/2478069/daily0.7https://crstodayeurope.com/news/hadley-launches-new-website-for-those-facing-vision-loss/2478068/daily0.7https://crstodayeurope.com/news/us-to-paynearly-2-billion-for-100-million-doses-of-pfizer-biontechs-covid-19-vaccine/2478067/daily0.7https://crstodayeurope.com/news/trump-administration-announces-5b-covid-19-relief-funds-future-testing-requirements-for-nursing-homes/2478064/daily0.7https://crstodayeurope.com/news/planning-ahead-u-s-canada-order-177m-more-covid-19-vaccine-syringes-from-bd/2478065/daily0.7https://crstodayeurope.com/news/aurinia-prices-200-million-public-offering-of-common-shares/2478066/daily0.7https://crstodayeurope.com/news/lacrivera-announces-ce-mark-of-the-vera180-synthetic-absorbable-lacrimal-plug/2478063/daily0.7https://crstodayeurope.com/news/updated-national-report-outlining-the-current-state-of-childrens-vision-and-eye-health/2478059/daily0.7https://crstodayeurope.com/news/study-points-to-potential-new-approach-to-treating-glaucoma-and-alzheimers-disease/2478060/daily0.7https://crstodayeurope.com/news/rayner-to-lower-carbon-footprint-by-more-than-800-tonnes-over-5-years/2478056/daily0.7https://crstodayeurope.com/news/another-problem-on-the-health-horizon-medicare-is-running-out-of-money/2478057/daily0.7https://crstodayeurope.com/news/eyecare-partners-announces-completion-of-six-new-practice-acquisitions-in-second-quarter/2478055/daily0.7https://crstodayeurope.com/news/alcon-survey-shows-more-screen-time-causing-consumer-concern-about-eye-health-increasing-symptoms-of-dry-eye/2478054/daily0.7https://crstodayeurope.com/news/nowrx-medly-pharmacy-land-new-funding-as-demand-for-digital-pharmacies-grows/2478052/daily0.7https://crstodayeurope.com/news/pfizer-biontechs-mrna-based-covid-19-vaccine-shows-promise-in-second-study/2478049/daily0.7https://crstodayeurope.com/news/gensight-biologics-reports-final-reality-study-confirms-poor-spontaneous-recovery-for-lhon-patients-with-nd4-mutation/2478050/daily0.7https://crstodayeurope.com/news/affroneye-saffron-extract-aims-to-reduce-risks-of-long-term-blue-light-induced-eye-injury/2478051/daily0.7https://crstodayeurope.com/news/glaucoma-study-findings-emphasize-need-for-regular-eye-checks/2478048/daily0.7https://crstodayeurope.com/news/tracking-aerosols-during-eye-surgeries/2478046/daily0.7